Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.151534910.3389/fphar.2024.1515349PharmacologyCorrectionCorrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cellsRossi et al.10.3389/fphar.2024.1515349RossiValentina1†Di ZazzoErika1†GalassoGiovanni1De RosaCaterina1AbbondanzaCiro1SinisiAntonio A.2AltucciLucia1MigliaccioAntimo1CastoriaGabriella1*1Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy2Dipartimento di Scienze Mediche, Chirurgiche, Neurologiche, Metaboliche e dell’Invecchiamento, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
Edited and reviewed by:Sergio Valente, Sapienza University of Rome, Italy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells by Rossi V, Di Zazzo E, Galasso G, De Rosa C, Abbondanza C, Sinisi AA, Altucci L, Migliaccio A and Castoria G (2019). Front. Pharmacol. 10:28. doi: 10.3389/fphar.2019.00028prostate cancerestrogenssomatostatin analogssomatostatin receptorsapoptosisEMTmigrationsection-at-acceptanceExperimental Pharmacology and Drug Discovery
In the published article, there was an error in Figure 5 as published. Figure 5C contained two different pictures representing different fields captured from the PPT-treated cells which had been assembled as two different conditions (PPT and E2+pas, respectively). Figure 5C should only contain an image captured from cells treated with E2+pas. The corrected Figure 5 and its caption appear below.
Effect of estradiol and pasireotide on EMT, morphology and motility of EPN cells. Quiescent EPN cells were untreated or treated for 48 h with the indicated compounds. Estradiol was used at 20 nM, pasireotide at 0.1 mM, PPT and DPN both at 3 nM. In panel (A), lysate proteins (2 mg/mL) were prepared, separated by SDS-PAGE and transferred to nitrocellulose membrane. Filters were immune-blotted using the antibodies against the indicated proteins. The blots are representative of two different experiments. In panel (B), the cells were analyzed for morphological changes using contrast-phase microscopy. Bar, 10 mM. In panel (C), the cells were wounded and then left unstimulated or stimulated with the indicated compounds. Cytosine arabinoside (20 mM) was added to the cell medium to avoid cell proliferation. Contrast-phase images in panel (B, C) are representative of 3 different experiments.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.